Related Experiment Video

Updated: Aug 16, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target

Colin Macphee1, G Martin Benson, Yi Shi

  • 1GlaxoSmithKline, Vascular Biology and Thrombosis, 709 Swedeland Road, King of Prussia, PA 19406, USA. colin.h.macphee@gsk.com

Expert Opinion on Investigational Drugs
|July 12, 2005
PubMed

Insights

Targeting lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) offers a novel approach to reduce cardiovascular risk beyond statins. Inhibiting this inflammatory enzyme may combat atherosclerosis progression and plaque instability.

Area of Science:

  • Cardiovascular Medicine
  • Inflammation Biology
  • Pharmacology

Background:

  • Statins offer limited protection (20-40%) against cardiovascular events, leaving significant residual risk.
  • Atherosclerosis is increasingly recognized as an inflammatory disease, prompting research into complementary therapies.
  • Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is an emerging inflammatory marker and potential therapeutic target in cardiovascular disease.

Purpose of the Study:

  • To evaluate the role of Lp-PLA(2) in atherosclerosis.
  • To explore the potential of Lp-PLA(2) inhibitors as a novel therapeutic strategy.
  • To assess the impact of Lp-PLA(2) inhibition on cardiovascular risk.

Main Methods:

  • Review of recent evidence on Lp-PLA(2) biological function in atherogenesis.
  • Analysis of Lp-PLA(2) association with low-density lipoprotein cholesterol (LDL-C).
  • Evaluation of initial clinical studies on Lp-PLA(2) inhibitors' efficacy.

Main Results:

  • Recent evidence supports a pro-atherogenic role for Lp-PLA(2).
  • Lp-PLA(2) activity generates lipid mediators that drive inflammation throughout atherogenesis.
  • Initial studies indicate Lp-PLA(2) inhibitors can reduce enzyme activity in plasma and plaques.

Conclusions:

  • Lp-PLA(2) plays a significant role in promoting inflammatory processes in atherosclerosis.
  • Inhibiting Lp-PLA(2) presents a promising complementary strategy to statins for cardiovascular risk reduction.
  • Further clinical studies are necessary to confirm the therapeutic benefits of Lp-PLA(2) inhibition.

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

High-Density Lipoprotein-Specific Phospholipid Efflux Assay07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

Related Concept Videos

Inflammation01:38

Inflammation

Overview
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...